The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The efficacy and safety of paclitaxel injection concentrate for nano-dispersion (PICN) at two different doses versus paclitaxel albumin-stabilized nanoparticle formulation in subjects with metastatic breast cancer (MBC).
Minish Mahendra Jain
No relevant relationships to disclose
Shekhar Patil
No relevant relationships to disclose
Anand Bhaskarrao Pathak
No relevant relationships to disclose
Chetan Dilip Deshmukh
No relevant relationships to disclose
Niraj Bhatt
No relevant relationships to disclose
K Govind Babu
No relevant relationships to disclose
Chiramana Haritha
No relevant relationships to disclose
Shailesh Arjun Bondarde
No relevant relationships to disclose
Raghunadharao Digumarti
Consultant or Advisory Role - Sun Pharma
Jyoti Bajpai
No relevant relationships to disclose
Ravi Kumar
No relevant relationships to disclose
Smita Uday Gupte
No relevant relationships to disclose
Ashish Vijay Bakshi
No relevant relationships to disclose
Gouri Shankar Bhattacharyya
No relevant relationships to disclose
Poonam Patil
No relevant relationships to disclose
S Subramanian
No relevant relationships to disclose
Ashok K. Vaid
No relevant relationships to disclose
Chirag Jyotiker Desai
No relevant relationships to disclose
P P Bapsy
No relevant relationships to disclose
Ganesh Divekar
Employment or Leadership Position - Sun Pharma